BioSpace News Archive

In addition to missing the mark in overall survival, Gilead reported Thursday a higher number of deaths in the Trodelvy arm of the confirmatory metastatic urothelial cancer study.

LSD, ketamine, ibogaine and related treatments are moving forward in clinical trials for substance use disorders, including alcohol use disorder and opioid use disorder.

While more programs now involve candidates with different targets, experts say anti-amyloid therapies will remain a primary player in treating the memory-robbing disease.

Invivyd, Inc., a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, announced general alignment with the U.S. Food and Drug Administration on an expedient, repeatable immunobridging pathway to future potential emergency use authorizations for serial, novel monoclonal antibodies for the prevention and treatment of symptomatic COVID-19.

Pfizer Inc. announced longer-term follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® versus XALKORI® in people with previously untreated, anaplastic lymphoma kinase -positive advanced non-small cell lung cancer.

Ocugen, Inc. announced a positive outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa clinical trial for OCU410 —a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age-related macular degeneration.

Capstan Therapeutics, Inc. announced that company management will participate in the upcoming 45th Annual Goldman Sachs Global Healthcare Conference, being held between June 10-13, 2024 at the Loews Miami Beach Hotel in Miami Beach, FL. Capstan will be hosting one-on-one meetings with investors.

Medicenna Therapeutics Corp. announced that comprehensive clinical results from the monotherapy dose escalation portion of the Phase 1/2 ABILITY-1 study evaluating MDNA11, in patients with advanced solid tumors, will be presented today at the 10th Annual Oncology Innovation Forum being held in Chicago.

The Alexander Shulgin Research Institute has unveiled a groundbreaking discovery in the journal Molecular Pharmacology: the first bifunctional compound that acts as both a 5-HT2A receptor antagonist and a voltage-gated sodium channel blocker.

Bavarian Nordic A/S announced the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration seeking approval of a freeze-dried formulation of JYNNEOS® for prevention of smallpox and mpox disease in adults 18 years of age and older.